Last $8.98 USD
Change Today +0.27 / 3.10%
Volume 1.7M
ARAY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

accuray inc (ARAY) Snapshot

Open
$8.67
Previous Close
$8.71
Day High
$9.07
Day Low
$8.66
52 Week High
03/11/14 - $10.16
52 Week Low
10/30/14 - $5.99
Market Cap
704.8M
Average Volume 10 Days
1.7M
EPS TTM
$-0.60
Shares Outstanding
78.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACCURAY INC (ARAY)

accuray inc (ARAY) Related Businessweek News

No Related Businessweek News Found

accuray inc (ARAY) Details

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its products in the United States directly, as well as through a sales agent and group purchasing organizations; and directly and through distributors in Europe, Japan and rest of Asia, South America, and internationally to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

1,026 Employees
Last Reported Date: 08/29/14
Founded in 1990

accuray inc (ARAY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $637.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $293.0K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $368.1K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $330.6K
Consultant
Total Annual Compensation: $154.7K
Compensation as of Fiscal Year 2014.

accuray inc (ARAY) Key Developments

Accuray Incorporated and Lancaster General Health Receive First Commercial InCise™ Multileaf Collimator for the CyberKnife® M6™ System

Accuray Incorporated and Lancaster General Health announced that the first commercially available InCise Multileaf Collimator (MLC) for the CyberKnife® M6 ¢ System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system's treatment efficiency and extend its unique capabilities to a broader range of patient cases. Evaluation of the InCise MLC with the CyberKnife M6 system has been successfully completed by two U.S. sites. Accuray conducted a rigorous evaluation of the device covering a wide range of functionality, performance, reliability and serviceability parameters. The InCise MLC successfully met all predetermined criteria to the company's and the sites' full satisfaction. Accuray is now working closely with its supply chain network to scale up manufacturing to meet commercial demand for the MLC. The InCise MLC is the world's first multileaf collimator to be available on a robotic platform, the CyberKnife M6 System. The system was designed to deliver extremely precise stereotactic body radiation therapy (SBRT). Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision. The CyberKnife M6 System can be used to treat tumors anywhere in the body, including the prostate, lung, brain, spine, liver, pancreas and kidney, and may offer hope to patients who have inoperable or surgically complex tumors, or who may prefer a clinically effective, non-surgical option.

Lancaster General Health Receives First Commercial InCise Multileaf Collimator for the CyberKnife M6 System

Accuray Incorporated and Lancaster General Health announced that the first commercially available InCise Multileaf Collimator (MLC) for the CyberKnife M6 System has been received by Lancaster. The hospital selected the InCise MLC based on its ability to increase the system's treatment efficiency and extend its unique capabilities to a broader range of patient cases. Evaluation of the InCise MLC with the CyberKnife M6 system has been successfully completed by two U.S. sites. Accuray conducted a rigorous evaluation of the device covering a wide range of functionality, performance, reliability and serviceability parameters. The InCise MLC successfully met all predetermined criteria to the company's and the sites' full satisfaction. Accuray is now working closely with its supply chain network to scale up manufacturing to meet commercial demand for the MLC.

Accuray Incorporated Awards Class A User Licenses for Accuray Products to 16 Hospitals

Accuray Incorporated announced that class A user licenses for Accuray products were awarded to 16 hospitals during February by the Chinese National Health and Family Planning Commission (NHFPC). TomoTherapy® System licenses were received by 12 hospitals and CyberKnife® System licenses were received by four hospitals. Of the 16 licenses just issued, Accuray believes that six licenses will allow orders already in backlog to be recognized as revenue in the near future and 10 licenses are expected to lead to new system orders entered into backlog in the coming months. The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series treatment solutions cover the entire spectrum of radiation therapy needs. The CyberKnife M6 Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system. The TomoTherapy H Series efficiently enables physicians to customize treatment plans for the entire range of radiation therapy patients and disease types. Its innovative design enables treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARAY:US $8.98 USD +0.27

ARAY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Elekta AB kr87.05 SEK -0.70
Koninklijke Philips NV €26.77 EUR +0.175
Mitsubishi Heavy Industries Ltd ¥662.70 JPY -3.20
RaySearch Laboratories AB kr73.75 SEK +1.00
Varian Medical Systems Inc $92.97 USD +0.52
View Industry Companies
 

Industry Analysis

ARAY

Industry Average

Valuation ARAY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.8x
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCURAY INC, please visit www.accuray.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.